Postal address
501 S. Santa Fe Ave., Suite 300,
Salina,  KS  67401
[map]

Telephone
785-452-4930

FAX
785-452-4932

General Information: veridian@srhc.com


powered by centersite dot net
Medications
Resources
Basic InformationMore InformationLatest News
Health Tip: Packing Prescriptions for TravelDrug Errors Peak in July When New Docs StartFDA Warns Consumers Against Swallowing Topical BenadrylStudy Shows Some Anti-Seizure Meds Raise Suicide RiskPrescriptions Translated to Spanish Could Be Hazardous to HealthTougher-to-Abuse Form of OxyContin ApprovedVaccines-By-Patch Good News for Needle-PhobicRifaximin Maintains Remission in Patients With Liver DiseaseMenstrual Cramps May Be Helped by New DrugNew Inhaled Insulin Shows Promise for DiabetesPlavix Can Help Cut Death Risk in Certain Heart PatientsFDA Asks Docs to Suspend Using Glaxo Rotavirus VaccineFDA Says High-Dose Simvastatin Ups Myopathy RiskHigh-Dose Zocor Boosts Muscle Injury Risk: FDAAvandia Researchers' Financial Ties QuestionedCarbaglu Approved for Rare Genetic DisorderACC: New Dual-Acting Drug Lowers Blood PressureNewer Blood Thinner Beats Plavix for Bypass PatientsArthritis Drug May Fight Diabetes, Too2 Drugs Fail to Prevent Diabetes in the OverweightFDA Adds Boxed Warning to Clopidogrel LabelThiazolidinediones Not Linked to Diabetic Macular EdemaYoung Kids to Benefit From Broader Pneumococcal VaccineBleeding Alert Sounded for Stroke DrugsLink Between Diabetes and Neuroleptic Drugs OutlinedResistance Likely to Develop With New Hepatitis C DrugsLasofoxifene Examined in Postmenopausal WomenSuccessor to Combination Pneumococcal Vaccine ApprovedMenveo Vaccine Approved for Bacterial MeningitisFDA: No Decision on Whether to Pull Diabetes Drug Avandia Off the MarketRituxan Approved for Chronic Lymphocytic LeukemiaNew Technology Could Widen Reach of VaccinesFDA Issues Warning on Key Asthma DrugsFDA Issues Maalox Total Relief WarningIbuprofen May Help Stave Off Parkinson'sFDA Tightens Controls on Anemia DrugsAdded Drug Aids MS Treatment'Fishy Smell' May Keep Patients From Diabetes DrugBotox May Prevent Some MigrainesAnother Study Refutes Vaccination-Autism LinkCrestor Approval ExpandedParoxetine May Compromise the Efficacy of TamoxifenNeedle Length May Affect Vaccination Results in ObeseDrug May Ease Cognitive Effects of Huntington'sGlaucoma Drugs May Play Role in Longer LifeH1N1 Vaccination Still Highly RecommendedThe Lancet Retracts Study Linking MMR Vaccine, AutismXiaflex Approved for Rare Hand ConditionAntidepressants After Stroke May Boost Mental AbilityFDA Revises Label for the HIV Drug Didanosine
Questions and AnswersLinksBook Reviews
Related Topics

Anxiety Disorders
Depression: Major Depression & Unipolar Varieties
Medical Disorders
Mental Disorders
Mental Health Professions

The Lancet Retracts Study Linking MMR Vaccine, Autism

HealthDay News
by -- Andrea Mongler
Updated: Feb 3rd 2010

new article illustration

WEDNESDAY, Feb. 3 (HealthDay News) -- On Feb. 2, The Lancet retracted a controversial 1998 study that linked the measles, mumps and rubella (MMR) vaccine to autism and gastrointestinal problems.

According to the journal's retraction, the U.K. General Medical Council's Fitness to Practise Panel found that several elements of the study -- by Andrew J. Wakefield, M.D., of the Royal Free Hospital in London, and colleagues -- were incorrect.

In the study, the researchers had looked at 12 children (mean age, 6 years), most of whom had been diagnosed with autism. They wrote that behavioral symptoms were associated -- by the parents -- with MMR vaccination in eight of the 12 children.

"The claims in the original paper that children were 'consecutively' referred and that investigations were 'approved' by the local ethics committee have been proven to be false. Therefore we fully retract this paper from the public record," The Lancet editors write in the retraction.

Retraction
Original Study